Man Infraconstruction Limited's Board of Directors met on October 29, 2026, and approved the un-audited financial results (consolidated and standalone) for the quarter and half-year ended September 30, 2026. The Board also approved material related party transactions, subject to shareholder approval via postal ballot. A limited review report from the statutory auditors, G. M. Kapadia & Co., was also presented.

Lake Shore Realty Limited has announced that its Board of Directors will convene on Monday, November 2, 2026. The primary agenda item is to consider and approve the Standalone Unaudited Financial Results for the quarter and half-year ending September 30, 2026, along with the Limited Review report. Additionally, the meeting will address any other business with the Chair's permission. The company also informed about the closure of the Trading Window for its equity shares from October 1, 2026, until 48 hours after the announcement of the financial results, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Apar Industries Ltd announced its un-audited financial results for the second quarter and half-year ended September 30, 2026. The Board of Directors approved the standalone and consolidated results. Additionally, the company reported the allotment of 2,720 equity shares under its ESARs plan, re-appointment of an Independent Director, and approved further investment of up to USD 100 Million in its wholly-owned subsidiary, Petroleum Specialties Pte Ltd., Singapore.

Manoj Ceramic Ltd has responded to a clarification sought by BSE regarding the recent significant movement in its security price. The company stated that all price-sensitive information has already been disclosed to the exchange within the stipulated time as per SEBI regulations. They confirmed there are no impending announcements and no material information has been withheld. Manoj Ceramic attributes the price movement to market sentiment, demand-supply dynamics, and investor activity, asserting that the company and its management are not connected to or in control of these market-driven fluctuations.

Sambhv Steel Tubes Limited's Board of Directors, in a meeting held on October 29, 2026, approved the establishment of a new Greenfield manufacturing facility for Stainless Steel Seamless Pipes and Tubes. This project will be undertaken by its wholly owned subsidiary, Sambhv Tubes Limited, in Chhattisgarh. The facility will have an initial capacity of 14,400 MTPA and an estimated investment of ₹1,480.00 million (₹148 Crore). The project is expected to be funded through a mix of debt and internal accruals, with completion targeted by March 2028. This expansion aims to bolster the company's presence in value-added steel products and meet growing market demand.

Man Infraconstruction's consolidated (primary basis) revenue from operations rose 57.2% YoY to ₹266.0 Cr and 21.9% QoQ, on a like-for-like basis against this filing's restated Sept-2025 comparative of ₹169.2 Cr (an Ind AS 1 reclassification moved JV/associate interest income into revenue this quarter, lifting both periods' revenue versus what was originally reported a year ago, when revenue was ₹148.75 Cr). Consolidated PAT (profit for the period) grew a far more modest 8.7% YoY and 4.0% QoQ to ₹65.2 Cr. Profit attributable to owners was ₹62.8 Cr, up 13.7% YoY but down 12.4% QoQ, a divergence from the headline PAT figure caused by non-controlling interest swinging from a ₹8.9 Cr loss position in Q1FY27 to a ₹2.5 Cr profit share this quarter — basic EPS fell to ₹1.56 from ₹1.77 in Q1FY27 even as it rose from ₹1.38 a year ago. The growth is almost entirely a Real Estate story: segment revenue jumped 90.2% YoY to ₹203.2 Cr (76% of net segment revenue), while EPC revenue was flat at ₹63.0 Cr (-0.2% YoY). Margins compressed on both measures: net profit margin eased to 23.1% from 26.7% (Q1FY27) and 32.1% (Q2FY26), and EBITDA-ex-other-income margin slipped to 30.3% from 32.8% and a restated 34.4% respectively. The squeeze shows up in Other Expenses, up 121.8% YoY to ₹52.6 Cr, and Finance Costs, up 94.7% YoY to ₹5.7 Cr — the latter notable against management's prior framing of a debt-free, ₹768 Cr-cash balance sheet. No brokerage consensus for this specific quarter turned up in search, so vs-street is unknown; no separate management press release accompanies this filing, so there is no company framing to reconcile against the print. Against management's own FY27 target of over 25% PAT growth over FY26 — already flagged as 'at risk' on the Q1 call — the quarter missed the pace badly: H1FY27 consolidated PAT is up just 8.1% YoY, roughly a third of the run-rate the full-year target implies. The quarter's buyback activity continued alongside the results: the Board's up-to-₹169.29 Cr buyback (69.25 lakh shares, ≤₹171/share) saw ₹87.67 Cr already spent on repurchases between September 9–30, 2026, presented as a deduction from Other Equity pending share extinguishment and not yet reflected in this quarter's EPS or share count. Going into H2FY27, the gap to the >25% full-year PAT growth target widens the bar for the back half, while the real estate-led revenue trajectory and finance-cost climb are the two numbers worth tracking against management's ₹5,000 Cr cumulative FY27-28 sales target and its no-debt positioning.

Senores Pharmaceuticals' consolidated (primary basis) Q2 FY27 revenue rose 24.9% YoY to ₹192.33 Cr (+6.7% QoQ vs ₹180.21 Cr in Q1 FY27), with consolidated PAT up 21.5% YoY to ₹36.60 Cr. EBITDA grew faster, up ~38% YoY to roughly ₹57.7 Cr, pushing the operating margin up ~290bps YoY to ~30% — management's own stated expansion. But that operating gain did not fully flow through: finance costs rose 42% YoY to ₹8.77 Cr and depreciation/amortisation rose 27% YoY to ₹10.25 Cr, while a ₹2.89 Cr net loss attributable to non-controlling interests — from the newly consolidated Zoraya and Amerisyn step-down subsidiaries, which are still in set-up with no matching revenue — pulled consolidated PAT below the ₹39.49 Cr actually earned by equity holders of the parent. Net profit margin was therefore roughly flat YoY at ~18.2% (18.0% a year ago) even as the EBITDA margin expanded. No brokerage-specific Q2 FY27 preview or consensus estimate could be found in a web search, so the print cannot be graded against street numbers (vsStreet: unknown). Against management's own FY27 guidance — reaffirmed in this release as 30-40% revenue growth and 50-60% PAT growth, with EBITDA margin of 29-31% — the quarter is a mixed scorecard: H1 FY27 revenue growth of 30% YoY sits at the low end of the guided band and H1 EBITDA margin of ~29.8% is within the guided range, but H1 PAT growth of just 31% YoY is well short of the 50-60% PAT guidance, meaning a sharp H2 acceleration is now required to hit the full-year target. Segment-wise, Regulated Markets revenue grew 27.9% YoY to ₹136.7 Cr and Emerging Markets grew 21.2% YoY to ₹38.4 Cr, while Branded Generics was the one segment drag, down 20.5% YoY to ₹9.5 Cr. Standalone and consolidated results diverge sharply — standalone PAT was just ₹7.72 Cr against ₹36.60 Cr consolidated — reflecting that the bulk of earnings now sit in the US/overseas subsidiary structure (Senores Pharma Inc, Havix, Ratnatris, Apnar and the new step-down subs), not the Indian parent. Management's press release frames this as its '9th consecutive quarter of healthy double-digit growth,' pointing to the ANDA portfolio nearly doubling YoY to 64 (23 commercialized, 41 more planned over the next 18-24 months) and pending Europe entry plus PIC/S approval for the Chhatral facility as growth drivers — claims the revenue and EBITDA numbers support, though the release does not directly address the PAT-growth shortfall against its own guidance. Corporate developments this quarter were largely administrative rather than result drivers: Swapnil Shah's reappointment as MD (Oct 13, 2026) signals leadership continuity, Talati & Talati LLP was appointed as a second joint statutory auditor alongside the incumbent, and a subsidiary's USFDA inspection concluded in September without disclosed findings — relevant context for the Regulated Markets ANDA pipeline but not a quantified financial driver this quarter.